|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.81 - 1.95|
|52 Week Range||1.70 - 10.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Sept. 13, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed a Letter of Intent with Impression Healthcare Limited, ...
NEW YORK, Aug. 27, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed an exclusive distribution and license agreement with Revive ...
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology-2018 (IDDST-2018), a conference focused on updating the breaking research of drug discovery and development for academic and industrial professionals, taking place in Cambridge, Mass. from August 16-19, 2018. AXIM’s Chief Technology Officer, Lekhram Changoer, will bring his expertise to this year’s event as a presenter on the topic of “Novel cGMP Technologies for Extraction, Purification, and Conversion of Cannabinoids for the Pharmaceutical Industry.” His presentation is scheduled to take place on Friday, August 17 from 3:30-3:50 p.m. ET in the Discovery Room, 3rd Floor as part of the Other Enabled Technologies for Drug Discovery session.
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced positive results from stability and dissolution tests performed on its prime drug candidate, MedChew Rx®, which will undergo clinical trials for the treatment of pain and spasticity in Multiple Sclerosis (MS) patients. Results showed that the primary Active Pharmaceutical Ingredients (APIs) in MedChew Rx™ remained stable throughout the test and that the availability of the APIs was greater than 90%. MedChew Rx® is comprised of the cannabinoid molecules delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which generally degrade after time.
NEW YORK, June 28, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28 th Annual International ...
OTC:AXIM Summary • AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company ...
SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its major investment company AXIM® ...
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. Regrettably, CANN is losing more and more money on marijuana services every year and is also burning cash.
• During the fourth quarter of 2017, cannabis stocks climbed sharply (North American Marijuana Index +137%) reflecting increased investor interest and positive fundamental tailwinds. • AXIM Biotechnologies is well positioned to benefit from the overall medical cannabinoid investment theme and is expected to achieve significant milestones during 2018. Making its debut on the Toronto Stock Exchange in April 2017, the Horizons Medical Marijuana Life Sciences ETF (HMMJ.TO) sought to mimic the North American Medical Marijuana Index, a basket of publicly-listed North American companies with significant business activities in the marijuana industry.
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market